ArticleNature2024
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers.
0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed
52.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 185 citations in OpenAlex.
- Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.British journal of haematology · 2026Trial
- Glutamine-driven metabolic reprogramming promotes CAR-T cell function through mTOR-SREBP2 mediated HMGCS1 upregulation in ovarian cancer.Journal of translational medicine · 2025Trial
- Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.Nature communications · 2024Trial
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion.Nature communications · 2026Article
- T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.Signal transduction and targeted therapy · 2026Review
- Oral nano-delivery of a gut microbial metabolite enhances T cell stemness for cancer immunotherapy.Nature nanotechnology · 2026Article
- Adoptive cell therapy in lung cancer: progress, challenges, and prospects.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.Leukemia · 2026Article
- Rewiring immunity with in vivo CAR T cell engineering.Nature cancer · 2026Review
- Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy.Immuno-oncology technology · 2026Article
- Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion.Journal of translational medicine · 2026Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy.Science advances · 2026Article
- Mechanisms, optimization strategies, and salvage options for CAR-T cell therapy.Biomarker research · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- Humanized biparatopic nanobody-based CAR-T cells overcome antigen-heterogeneity in multiple myeloma.Journal of translational medicine · 2026Article
- Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.Nature communications · 2026Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 4 institutions in 1 country.
Jack D Chan *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-5942-8592
Christina M Scheffler *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3731-6204
Isabelle Munoz *Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-6510-5696
Kevin SekCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-4634-7600
Joel N LeeCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Yu-Kuan HuangCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-2262-7069
Kah Min YapCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-5009-9895
Nicole Y L SawCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jasmine LiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Amanda X Y ChenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Cheok Weng ChanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Emily B DerrickCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-7191-3948
Kirsten L ToddCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-3903-166X
Junming TongCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0009-0006-6454-8704
Phoebe A DunbarCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jiawen LiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Thang X HoangCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Maria N de MenezesCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3231-0620
Emma V PetleyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Joelle S KimCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Dat NguyenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Patrick S K LeungSchool of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
Joan SoSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-6550-0637
Christian DeguitCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-0759-4035
Joe ZhuCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-4416-7040
Imran G HouseCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-6245-5954
Lev M KatsSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-8742-8138
Andrew M ScottOlivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
Benjamin J SolomonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-3059-5730
Simon J HarrisonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-4555-6582
Jane OliaroCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-2097-6428
Ian A ParishCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-3528-478X
Kylie M QuinnSchool of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.ORCID 0000-0002-0417-3625
Paul J NeesonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-2729-5887
Clare Y SlaneyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Junyun LaiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. junyun.lai@unimelb.edu.au.ORCID 0000-0001-5884-2786
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. paul.beavis@petermac.org.ORCID 0000-0002-2116-013X
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. phil.darcy@petermac.org.ORCID 0000-0002-5303-9561
The University of Melbourne · AUMonash University · AUPeter MacCallum Cancer Centre · AURMIT University · AU
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of haematological malignancies such as acute lymphoblastic leukaemia, B cell lymphoma and multiple myeloma
Indexed as
Forkhead Box Protein O1Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenStem CellsT-LymphocytesAnimalsCell Line, TumorHumansMiceMitochondriaPhenotypeTumor MicroenvironmentForkhead Box Protein O1FOXO1 protein, humanReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.